Larotrectinib (Vitrakvi) capsule，拉罗替尼胶囊

Larotrectinib is a broad-spectrum anticancer drug and also a targeted therapy drug. Its main efficacy and function is to treat locally advanced or metastatic solid tumors. Larotrectinib is recommended as a first-line treatment option for patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive metastatic non-small cell lung cancer.

Larotrectinib is an NTRK gene inhibitor. NTRK gene fusion has been found in many tumors such as lung cancer, melanoma, and breast cancer. Larotrectinib is the first choice for treating such tumors, especially for infantile fibrosarcoma and childhood osteosarcoma.

Larotrectinib can inhibit the growth and proliferation of tumor cells by inhibiting tropomyosin receptor kinase. It can also treat cancers such as gastric cancer, colon cancer, thyroid cancer, appendix cancer, and soft tissue sarcoma.

Larotrectinib is a new anticancer drug that only targets specific gene mutations, not limited to specific types of cancer. Although the drug is relatively effective, its research and development costs are relatively high, so the cost is also relatively expensive.

Its common adverse reactions include fever, abdominal pain, diarrhea, etc. Patients need to take the drug under the guidance of a doctor. People with allergies should avoid taking this medicine to avoid causing physical damage. During the medication period, they should also avoid changing the dosage or stopping the medication on their own to avoid further aggravation of the condition.